Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 10, Issue 15, Pages 2395-2397Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656560903176453
Keywords
cardiovascular disease; diabetes mellitus; metformin; oral hypoglycaemic agents
Categories
Ask authors/readers for more resources
Metformin has now been established as the drug of choice for the first-line management of type 2 diabetes mellitus. It reduces insulin resistance, improves glycaemic control, and can be safely combined with other classes of oral hypoglycaemic agents. Equally important, metformin has been shown to have a significant beneficial effect on cardiovascular morbidity. Moreover, this agent acts favourably on blood pressure, lipids, haemostasis and other features of the metabolic syndrome. Metformin also contributes to weight reduction and diabetes prevention.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available